Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera; and SurgiBot System, a single-port robotically enhanced laparoscopic surgical platform. Its products also comprise instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is based in Durham, North Carolina.
IPO Year:
Exchange: AMEX
Website: asensus.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/16/2023 | Overweight → Neutral | Cantor Fitzgerald | |
| 9/8/2022 | $1.50 | Overweight | Cantor Fitzgerald |
| 9/8/2022 | $1.50 | Buy | Stifel |
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
Cantor Fitzgerald downgraded Asensus Surgical from Overweight to Neutral
Cantor Fitzgerald initiated coverage of Asensus Surgical with a rating of Overweight and set a new price target of $1.50
Stifel initiated coverage of Asensus Surgical with a rating of Buy and set a new price target of $1.50
HC Wainwright & Co. initiated coverage of Asensus Surgical with a rating of Buy and set a new price target of $4.00
Raymond James resumed coverage of Asensus Surgical with a rating of Hold
RESEARCH TRIANGLE PARK, N.C. and TUTTLINGEN, Germany, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC) ("Asensus Surgical" or "Asensus"), a global leader of innovative digital solutions for the operating room, today announced the closing of the merger (the "Merger") with the KARL STORZ Group ("KARL STORZ"). The transaction was completed following approval by the Asensus Surgical stockholders. Under the terms of the merger agreement, KARL STORZ Endoscopy-America, Inc., a wholly owned direct subsidiary of KARL STORZ, has acquired all outstanding shares of Asensus Surgical for $0.35 per share in cash. As a result of the acquisition, Asensus Surgical has become a sub
RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, announced its operating and financial results for the second quarter 2024. Recent Highlights Announced a definitive merger agreement (the "Merger Agreement") with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"), a wholly owned direct subsidiary of KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company. Under the Merger Agreement, KARL STORZ will acquire all of the outstanding shares of Asensus Surgical for $0.35 per share in cash (the "Merger")Leading independent proxy advisory firms,
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 second quarter financial and operating results after the market closes on Tuesday, August 13, 2024. The Company will host a conference call to discuss these results and the status of the proposed merger with KARL STORZ starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-800-717-1738 for domesticcallers and 1-646-307-1865 for international callers, approximately
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, today announced that the Company's Special Meeting of Stockholders, scheduled to be held on Wednesday, August 7, 2024 at 10:00 a.m. (Eastern Time), was adjourned to Tuesday, August 20, at 10:00 a.m. (Eastern Time). The Special Meeting will be held virtually. While we have received proxies for approximately 52% of our outstanding shares with a large majority voted in favor of the merger proposal, we still need more votes to approve the transaction. This is a very low turnout for such an important vote and we en
RESEARCH TRIANGLE PARK, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), became the second advisory firm to recommend that Asensus Surgical stockholders vote "FOR" all proposals relating to the pending merger transaction with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"). The vote will take place at the Company's upcoming Special Meeting of Stockholders to be held virtually at 10:00 a.m. Eastern Time on August 7, 2024. ISS is widely recognized as a leading independent voting a
RESEARCH TRIANGLE PARK, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, announced today that a leading independent proxy advisory firm, Glass, Lewis & Co. ("Glass Lewis"), has recommended that Asensus Surgical stockholders vote "FOR" all proposals relating to the pending merger transaction with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"). The vote will take place at the Company's upcoming Special Meeting of Stockholders to be held virtually at 10:00 a.m. Eastern Time on August 7, 2024. Glass Lewis is widely recognized as a leading independent voting and corporate governance advisory f
RESEARCH TRIANGLE PARK, N.C., July 24, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, announced that The Rocky Mountain Hospital for Children in Denver, Colorado, part of HCA Healthcare's HealthONE network, has entered into an agreement to utilize a Senhance® Surgical System. "We are thrilled to announce the first dedicated pediatric hospital placement of a Senhance® System in the United States," stated Anthony Fernando, President and CEO of Asensus Surgical. "This reflects our shared commitment to innovation and patient-centered care, with the ultimate goal of improving the lives of children undergo
RESEARCH TRIANGLE PARK, N.C., July 23, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a global leader of innovative digital solutions for the operating room, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for an expanded indication to treat adult and pediatric Urology patients with the Senhance® Surgical System. "This FDA clearance marks another milestone for Asensus Surgical and represents an additional indication expansion in the U.S. market," said Anthony Fernando, Asensus Surgical President and CEO. "The Senhance System's precision and advanced digital capabilities make it uniquely suited for urological procedures
RESEARCH TRIANGLE PARK, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and patient, announced that LKH-Universitätsklinikum Graz in Austria has entered into an agreement to lease and utilize a Senhance® Surgical System. LKH-Universitätsklinikum Graz is a renowned healthcare institution known for its expertise in minimally invasive pediatric and adolescent surgery. This hospital will be the 7th pediatric-focused site to utilize the state-of-the-art Senhance Surgical System using 3mm and 5mm instruments for a variety of minimally invasive procedures. "We are thrilled to collaborate wi
RESEARCH TRIANGLE PARK, N.C., June 24, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, today announced that St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan has entered into an agreement to lease and utilize a Senhance® Surgical System in the Urology and Gastroenterology/General Surgery department. "We are excited to collaborate with the St. Marianna University School of Medicine Yokohama City Seibu Hospital to bring our Senhance Surgical System to this innovative institution," said Anthony Fernando, President and CEO of Asensus Surgical. "Powered b
15-12G - ASENSUS SURGICAL, INC. (0000876378) (Filer)
EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)
EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)
EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)
EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)
EFFECT - ASENSUS SURGICAL, INC. (0000876378) (Filer)
S-8 POS - ASENSUS SURGICAL, INC. (0000876378) (Filer)
S-8 POS - ASENSUS SURGICAL, INC. (0000876378) (Filer)
S-8 POS - ASENSUS SURGICAL, INC. (0000876378) (Filer)
S-8 POS - ASENSUS SURGICAL, INC. (0000876378) (Filer)
Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing two new board members, Elizabeth Kwo, MD and Kevin Hobert, effective immediately. "We are delighted to welcome two accomplished industry veterans to our Board of Directors, each of whom bring highly relevant and unique skills to the organization that complement our current leadership team in an impactful way," said Paul LaViolette, Chairman of the Board of Asensus Surgical. "Liz has a tremendous track record of bringing innovative healthcare t
BOTHELL, Wash., May 28, 2021 (GLOBE NEWSWIRE) -- With great sadness, Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company") announces that Gary Wilcox, Ph.D., Chairman, CEO and co-founder, suddenly passed away Wednesday, May 26 at the age of 74. The Board of Directors and staff of Cocrystal extend their deepest condolences to the Wilcox family and express their gratitude for Gary's contributions to Cocrystal and to human health. The Cocrystal Board of Directors has designated Sam Lee, Ph.D., President, and James Martin, CFO, to share the CEO responsibilities while seeking a successor for the position. Roger Kornberg, Ph.D., Cocrystal co-founder, Chief Scientist, Director and
SC 13G - ASENSUS SURGICAL, INC. (0000876378) (Subject)
SC 13G/A - ASENSUS SURGICAL, INC. (0000876378) (Subject)
SC 13G - ASENSUS SURGICAL, INC. (0000876378) (Subject)
4 - ASENSUS SURGICAL, INC. (0000876378) (Issuer)
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 second quarter financial and operating results after the market closes on Tuesday, August 13, 2024. The Company will host a conference call to discuss these results and the status of the proposed merger with KARL STORZ starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-800-717-1738 for domesticcallers and 1-646-307-1865 for international callers, approximately
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 first quarter financial and operating results after the market closes on Tuesday, May 14, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time. To access the live audi
RESEARCH TRIANGLE PARK, N.C., March 15, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, March 21, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time. To
RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient announced today that it plans to release 2023 third quarter financial and operating results after the market closes on Tuesday, November 14, 2023. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time. To access the live
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release 2023 second quarter financial and operating results after the market closes on Thursday, August 10, 2023. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-844-826-3033 for domestic callers and 1-412-317-5185 for international callers, approximatel
RESEARCH TRIANGLE PARK, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the first quarter 2023. Recent Highlights 20% year-over-year growth in surgical procedures, with over 900 procedures performed globally during the quarterSurpassed 10,000 procedures on Senhance® Surgical SystemOne Senhance Surgical Program was initiated during the quarterIn March 2023, received FDA 510(k) clearance for an expanded indication to treat pediatric patientsIn January 2023, receiv
RESEARCH TRIANGLE PARK, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™ (PGS), announced today that it plans to release 2023 first quarter financial and operating results after the market closes on Thursday, May 11, 2023. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial 1-844-826-3033 for domestic callers and 1-412-317-5185 for international callers, approximate
RESEARCH TRIANGLE PARK, N.C., March 02, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™(PGS), today announced its operating and financial results for the fourth quarter and full year 2022. As the Company hosted an Investor Day on Tuesday, February 21, 2023 during which an in-depth review of the business was provided, the Company will not be hosting an earnings conference call in conjunction with this earnings release. Recent Highlights In February 2023, unveiled plans for the LUNA™ Surgical System, its next generation digital surg
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release fourth quarter and full year 2022 financial and operating results after the market closes on Thursday, March 2, 2023. As the Company hosted an Investor Day on Tuesday, February 21, 2023 during which an in-depth review of the business was provided, the Company will not be hosting an earnings conference call in conjunction with its earnings release. A video replay of the Investor Day presentation is ava
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the third quarter 2022. Recent Highlights Over 1,900 procedures were performed globally during the nine months ended September 30, 2022, representing growth of 27% over the prior yearFive new Senhance program initiations year to date, 3 in Germany, 1 in Japan, 1 in CIS regionSubmitted FDA 510(k) application for pediatric indication in the U.S.Received the Society of Laparoscopic & Robotic S
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 0.1% on Friday. The Dow traded up 0.12% to 38,931.98 while the NASDAQ fell 0.09% to 17,156.98. The S&P 500 also rose, gaining, 0.11% to 5,359.05. Check This Out: Vail Resorts, DocuSign And 3 Stocks To Watch Heading Into Friday Leading and Lagging SectorsFinancial shares climbed by 0.7% on Friday. In trading on Friday, real estate shares dipped by 0.8%. Top Headline The total number of active U.S. oil rigs fell by four to 492 rigs this week, Baker Hughes Inc reported. Equities Trading UP Venus Concept Inc. (NASDAQ:VERO) shares shot up 74% to $1.0776 on
Shares of GameStop Corp. (NYSE:GME) fell sharply during Friday's session after the company released worse-than-expected first-quarter results before schedule and filed to sell up to 75 million shares. GameStop released its first-quarter 2024 results early Friday ahead of its scheduled June 11 date. The company reported net sales of $881.8 million, down from $1.237 billion year-over-year. The net sales total missed a consensus estimate of $995.3 million. The company reported a loss of 12 cents per share, missing the estimate of a loss of 9 cents per share, according to data from Benzinga Pro. GameStop shares dipped 22.5% to $36.07 on Friday. Here are some other stocks moving in today
Gainers Venus Concept (NASDAQ:VERO) shares rose 87.9% to $1.1 during Friday's regular session. The company's market cap stands at $7.0 million. Asensus Surgical (AMEX:ASXC) stock moved upwards by 41.22% to $0.33. The market value of their outstanding shares is at $90.3 million. American Oncology Network (NASDAQ:AONC) shares rose 29.41% to $2.2. The market value of their outstanding shares is at $22.4 million. Anebulo Pharmaceuticals (NASDAQ:ANEB) shares rose 29.33% to $2.8. The market value of their outstanding shares is at $72.6 million. IN8bio (NASDAQ:INAB) stock increased by 22.12% to $1.38. The market value of their outstanding shares is at $60.8 million. Geron (NASDAQ:GERN) stock
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.12% to 38,934.29 while the NASDAQ fell 0.06% to 17,163.20. The S&P 500 also rose, gaining, 0.06% to 5,356.10. Check This Out: Vail Resorts, DocuSign And 3 Stocks To Watch Heading Into Friday Leading and Lagging SectorsFinancial shares climbed by 0.8% on Friday. In trading on Friday, real estate shares dipped by 1.1%. Top Headline U.S. wholesale inventories increased by 0.1% month-over-month in April compared to the advance reading of a 0.2% increase and versus a revised 0.5% declined in the previous month. Equities Trading UP
On Friday, KARL STORZ Endoscopy-America, Inc. agreed to acquire Asensus Surgical Inc. (NYSE:ASXC) for $0.35 per share in cash. KARL STORZ is a wholly-owned direct subsidiary of KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company based in Germany. The purchase price represents a premium of approximately 67% based on the per-share closing price of the Asensus common stock on the NYSE American on April 2 and a premium of approximately 52% to the closing price of the common stock on the last trading day prior to the date of this announcement. In April, Asensus entered into a non-binding letter of intent with KARL STORZ to engage in diligence and negoti
KARL STORZ to acquire Asensus for $0.35 per share in cash Creating a leading surgical robotics division within KARL STORZRESEARCH TRIANGLE PARK, N.C., June 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC) ("Asensus Surgical" or "Asensus"), a global leader of innovative digital solutions for the operating room, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"), a wholly owned direct subsidiary of KARL STORZ SE & Co. KG, an independent, family-owned global medical technology company. Under the Merger Agreement, KARL STORZ will acquire all of the outstanding shares of Asensus Surg